Abstract
Chemotherapy is the primary means of treating protozoan parasitic infections. A problem for chemotherapy is to find a novel and potential molecule in protozoa, which could be exploited as drug target. To reach this goal, mitochondrion of protozoa can be considered as the most valuable and potential organelle because of its unique structure and function compared to their natural host habitat. In fact, the respiratory systems of parasitic protozoa typically show greater diversity in electron pathways than do their host animals. These unique aspects of electron transport chain (ETC) complexes and their related enzymes represent promising targets for chemotherapy. A cytochrome independent Alternative Oxidase (AOX) in parasites is a leading drug target. Topoisomerases play key functions in replication and organization of kDNA, which is present in a specialized region of unique mitochondria known as kinetoplast. They are considered as potential targets for anti-parasitic drugs. Moreover, a novel pathway of type II Fatty acid synthesis in mitochondria of trypanosomatids provides a new array of inhibitors that could be effective against these parasites. Recent studies on the emergence of drug resistance severely limit the arsenal of available drugs against protozoan parasites. Particularly, mutations of cytochrome b gene of ETC or changes in iron homeostasis by mitochondrial enzyme aconitase alter sensitivity of MDR1 and regulate resistance level to anti-parasitic drugs. This review summarizes recent state of our knowledge and understanding of the action of various therapeutically applied substances on mitochondria and their potential application in the future.
Keywords: Mitochondria, protozoa, electron transport chain, fatty acid synthesis, alternative oxidase, topoisomerase, drug resistance, apoptosis
Current Pharmaceutical Design
Title: Mitochondrion of Protozoan Parasite Emerges as Potent Therapeutic Target:Exciting Drugs are on the Horizon
Volume: 14 Issue: 9
Author(s): Nilkantha Sen and Hemanta K. Majumder
Affiliation:
Keywords: Mitochondria, protozoa, electron transport chain, fatty acid synthesis, alternative oxidase, topoisomerase, drug resistance, apoptosis
Abstract: Chemotherapy is the primary means of treating protozoan parasitic infections. A problem for chemotherapy is to find a novel and potential molecule in protozoa, which could be exploited as drug target. To reach this goal, mitochondrion of protozoa can be considered as the most valuable and potential organelle because of its unique structure and function compared to their natural host habitat. In fact, the respiratory systems of parasitic protozoa typically show greater diversity in electron pathways than do their host animals. These unique aspects of electron transport chain (ETC) complexes and their related enzymes represent promising targets for chemotherapy. A cytochrome independent Alternative Oxidase (AOX) in parasites is a leading drug target. Topoisomerases play key functions in replication and organization of kDNA, which is present in a specialized region of unique mitochondria known as kinetoplast. They are considered as potential targets for anti-parasitic drugs. Moreover, a novel pathway of type II Fatty acid synthesis in mitochondria of trypanosomatids provides a new array of inhibitors that could be effective against these parasites. Recent studies on the emergence of drug resistance severely limit the arsenal of available drugs against protozoan parasites. Particularly, mutations of cytochrome b gene of ETC or changes in iron homeostasis by mitochondrial enzyme aconitase alter sensitivity of MDR1 and regulate resistance level to anti-parasitic drugs. This review summarizes recent state of our knowledge and understanding of the action of various therapeutically applied substances on mitochondria and their potential application in the future.
Export Options
About this article
Cite this article as:
Sen Nilkantha and Majumder K. Hemanta, Mitochondrion of Protozoan Parasite Emerges as Potent Therapeutic Target:Exciting Drugs are on the Horizon, Current Pharmaceutical Design 2008; 14 (9) . https://dx.doi.org/10.2174/138161208784041024
DOI https://dx.doi.org/10.2174/138161208784041024 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Current Pharmaceutical Design Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Exploring the Mechanism of Lingzhu San in Treating Febrile Seizures by Using Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Inhibitory Role of Resveratrol in the Development of Profibrogenesis and Fibrosis Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) MicroRNAs: Modulators of Cell Identity, and their Applications in Tissue Engineering
MicroRNA Laboratory Monitoring of Hematological and Hepatic Parameters in Ambulatory Patients Receiving Alpha-Methyldopa in a Nigerian Tertiary Care Setting
Current Drug Safety Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery New Viral Infection COVID-19: Current Status, Challenges and Possible Treatments
Letters in Drug Design & Discovery GRK2 Inhibition in Heart Failure: Something Old, Something New
Current Pharmaceutical Design 2-Chloroadenosine and Human Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Diagnostic Value of the Early Heart-to-Mediastinum Count Ratio in Cardiac 123I-mIBG Imaging for Parkinson's Disease
Current Radiopharmaceuticals Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Role of NADPH Oxidase in Hypertension and Diabetic Nephropathy
Current Hypertension Reviews Role of Nanomedicine in Hepatic Targeting- Deciphering Strategies with Molecular Insights and Preclinical Prospects
Drug Delivery Letters Marine Collagen as a Source of Bioactive Molecules: A Review
The Natural Products Journal Gene Therapy for Gastric Diseases
Current Gene Therapy Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Editorial[Hot Topic:Stem Cell Therapy for Cardiovascular Diseases:Are We Still at the Beginning of A Long Road?(Guest Editor:Lino M Goncalves)
Cardiovascular & Hematological Disorders-Drug Targets Antiangiogenic Agents: Studies on Fumagillin and Curcumin Analogs
Current Pharmaceutical Design Collagen Cross-link Breakers:A Beginning of a New Era in the Treatment of Cardiovascular Changes Associated with Aging,Diabetes,and Hypertension
Current Drug Targets - Cardiovascular & Hematological Disorders